Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
Background/Purpose: Pertussis cases have increased worldwide and knowledge on immune response after adult Tdap vaccine is scarce. This study evaluated the humoral immune response profile after Tdap in children and adolescents with Juvenile Idiopathic Arthritis and in healthy controls.
Methods: After written informed consent, children and adolescents with Juvenile Idiopathic Arthritis (JIA) using anti-TNF and healthy controls (control) with three previous whole-cell DTP plus two booster vaccine doses received a Tdap dose. Blood samples were collected immediately before and 28 days after Tdap. Tetanus, diphtheria and pertussis antibodies were tested by ELISA. Antibodies>0.100 IU/mL were considered protective for tetanus and diphtheria. There isn’t a consensus antibodies level considered protective for pertussis.
Results: JIA group (n=10) was represented for 7 (70%) female, with median age 13 (8-18), 4 (40%) with positive anti-nuclear antibodies (ANA), 1 (10%) with positive rheumatoid factor. Control group (n=9) was represented for 4 (44.4%) female, with median age 15.2 (9-15.6). JIA and control groups presented an increase in response to tetanus (p=0.0004, p=0.002) and diphtheria (p<0.0001, p=0.002) antibodies after Tdap booster dose on day 28 and were comparable in the proportion of immune subjects on day 0 (p=0.1226, p=0.3322) and on day 28 (p=0.3493, p=0.5). Everyone in both groups seroconverted to tetanus and diphtheria. In JIA group median antibodies level for pertussis were 10.796 IU/mL (2.4-197.09) and 83.8 IU/mL (8.4-196.69) on day 0 and day 28. In the control group median antibodies level for pertusis were 8.47 IU/mL (1.08-108.88) and 59.73 IU/mL (13.87-138.04) on day 0 and day 28.
Conclusion: In this preliminary study, children and adolescents with JIA using anti-TNF and healthy controls showed adequate humoral immune response to tetanus, diphtheria and pertussis after Tdap. Future research include increasing sample size correlating T follicular cells population with improved humoral immune response.
To cite this abstract in AMA style:Nicacio A, Peracchi O, Yamada J, Spina F, Alvarenga B, Pinto MI, Terreri MT. Humoral Immune Response after a Booster Dose with Tdap in Children and Adolescents with Juvenile Idiopathic Arthritis on Anti-TNF and in Healthy Controls [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/humoral-immune-response-after-a-booster-dose-with-tdap-in-children-and-adolescents-with-juvenile-idiopathic-arthritis-on-anti-tnf-and-in-healthy-controls/. Accessed November 29, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/humoral-immune-response-after-a-booster-dose-with-tdap-in-children-and-adolescents-with-juvenile-idiopathic-arthritis-on-anti-tnf-and-in-healthy-controls/